TSC1 and neoplasm: Combination therapy produced intermediate tumor proliferation and CD8+ T cell infiltration, suggesting partial but incomplete reversal of TSC1 deficiency–induced immune evasion, likely constrained by additional immunosuppressive pathways such as IDO1 induction or Treg recruitment.